Sökning: "rituximab"

Visar resultat 6 - 10 av 61 avhandlingar innehållade ordet rituximab.

  1. 6. AB0-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab

    Författare :Helena Genberg; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : 5As the demand for kidney transplantation is constantly growing methods to expand the donor pool have become increasingly important. AB0-incompatibility has hitherto been regarded as an absolute contraindication to living donor donation. LÄS MER

  3. 7. Follicular and Diffuse Large B-Cell Lymphoma - Studies of Primary Treatment and Prognostic Factors

    Författare :Elisabeth Szekely; Tumörmikromiljö; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; diffuse large B-cell lymphoma; ; follicular lymphoma; ; prognostic factors; ; etoposide; chemotherapy regimen; seasonal variation; gender; watch and wait; rituximab monotherapy;

    Sammanfattning : .... LÄS MER

  4. 8. Pharmacoepidemiological studies of rituximab and other recent therapies in multiple sclerosis

    Författare :Peter Alping; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Multiple Sclerosis (MS) is a chronic autoimmune disorder of the central nervous system, characterized by the accumulation of demyelinating inflammatory lesions. Milder cases exist, but most patients eventually develop severe neurological symptoms and disability. LÄS MER

  5. 9. B cell depleting therapy in systemic lupus erythematosus

    Författare :Thórunn Jónsdóttir; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :Systemic Lupus Erythematosus; Lupus nephritis; B cells; rituximab;

    Sammanfattning : Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by multiple organ involvement, production of a wide range of autoantibodies and local formation or tissue deposition of immune complexes in the affected organs. Lupus nephritis (LN) is a common and serious organ involvement in patients with SLE. LÄS MER

  7. 10. Anti-CD20 therapy in multiple sclerosis : clinical and paraclinical outcomes

    Författare :Alexander Juto; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Multiple sclerosis is a chronic inflammatory disease of the central nervous system and the most common non-traumatic cause of neurological disability in young adults. Rituximab is a B-cell depleting drug targeting the CD20 epitope on B-cells, which drive inflammation in relapsing-remitting multiple sclerosis by acting as antigen-presenting cells to activate T-cell responses against central nervous system autoantigens. LÄS MER